Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement

Lewis, Lisa A, Gulati, Sunita, Zelek, Wioleta M., Morgan, B. Paul ORCID: https://orcid.org/0000-0003-4075-7676, Song, Wen-Chao, Zheng, Bo, Nowak, Nancy, DeOliveira, Rosane B., Sanchez, Bryan, DeSouza Silva, Leandro, Schuurman, Janine, Beurskens, Frank, Ram, Sanjay and Rice, Peter A 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225 (10) , 1861–1864. 10.1093/infdis/jiab630

Preview

PDF - Accepted Post-Print Version Download (611kB) | Preview

Abstract

A safe and effective vaccine against multidrug-resistant gonorrhea is urgently needed. An experimental peptide vaccine called TMCP2 that mimics an oligosaccharide epitope in gonococcal lipooligosaccharide, when adjuvanted with glucopyranosyl lipid adjuvant–stable emulsion, elicits bactericidal immunoglobulin G and hastens clearance of gonococci in the mouse vaginal colonization model. In this study, we show that efficacy of TMCP2 requires an intact terminal complement pathway, evidenced by loss of activity in C9−/− mice or when C7 function was blocked. In conclusion, TMCP2 vaccine efficacy in the mouse vagina requires membrane attack complex. Serum bactericidal activity may serve as a correlate of protection for TMCP2.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Oxford University Press
ISSN:	0022-1899
Date of First Compliant Deposit:	4 July 2022
Date of Acceptance:	30 December 2021
Last Modified:	02 Dec 2024 06:00
URI:	https://orca.cardiff.ac.uk/id/eprint/150977

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item